CVS Health Corp Company Profile (NYSE:CVS)

About CVS Health Corp (CVS)

CVS Health Corp logoCVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc. (Omnicare) and Omnicare's long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. It operates through three segments: Pharmacy Services, Retail/LTC and Corporate. The Pharmacy Services Segment provides a range of pharmacy benefit management (PBM) solutions to its clients. As of December 31, 2016, the Retail/LTC Segment included 9,709 retail locations (of which 7,980 were its stores that operated a pharmacy and 1,674 were its pharmacies located within Target Corporation (Target) stores), its online retail pharmacy Websites,, and, 38 onsite pharmacy stores, its long-term care pharmacy operations and its retail healthcare clinics.

Industry, Sector and Symbol:
  • Sector: Retail/Wholesale
  • Industry: Health Care Plans
  • Sub-Industry: Drug Retail
  • Exchange: NYSE
  • Symbol: CVS
  • CUSIP: 12665010
Key Metrics:
  • Previous Close: $82.79
  • 50 Day Moving Average: $79.00
  • 200 Day Moving Average: $79.96
  • 52-Week Range: $69.30 - $106.67
  • Trailing P/E Ratio: 16.86
  • Foreward P/E Ratio: 13.00
  • P/E Growth: 1.16
  • Market Cap: $87.84B
  • Outstanding Shares: 1,061,000,000
  • Beta: 0.85
  • Net Margins: 3.00%
  • Return on Equity: 17.55%
  • Return on Assets: 6.74%
  • Debt-to-Equity Ratio: 0.70%
  • Current Ratio: 1.18%
  • Quick Ratio: 0.62%

Analyst Ratings

Consensus Ratings for CVS Health Corp (NYSE:CVS) (?)
Ratings Breakdown: 6 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.68)
Consensus Price Target: $96.82 (16.94% upside)

Analysts' Ratings History for CVS Health Corp (NYSE:CVS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/27/2017Tigress FinancialInitiated CoverageBuyLowView Rating Details
4/1/2017Jefferies Group LLCSet Price TargetHold$82.00LowView Rating Details
3/28/2017GuggenheimReiterated RatingBuy$90.00LowView Rating Details
3/18/2017Leerink SwannSet Price TargetBuy$90.00LowView Rating Details
2/28/2017Bank of America CorpReiterated RatingBuy$106.67N/AView Rating Details
2/9/2017Evercore ISILower Price TargetBuy$91.50 -> $84.00N/AView Rating Details
2/8/2017Deutsche Bank AGReiterated RatingHold$88.00N/AView Rating Details
2/6/2017Atlantic SecuritiesDowngradeOverweight -> Neutral$84.00N/AView Rating Details
2/2/2017Robert W. BairdDowngradeOutperform -> Neutral$86.00 -> $77.00N/AView Rating Details
12/19/2016Credit Suisse Group AGReiterated RatingBuyN/AView Rating Details
12/18/2016Oppenheimer Holdings Inc.Set Price TargetBuy$88.00N/AView Rating Details
11/10/2016ArgusReiterated RatingBuy$120.00 -> $85.00N/AView Rating Details
11/9/2016Barclays PLCReiterated RatingBuy$85.00N/AView Rating Details
11/9/2016MizuhoBoost Price TargetBuy$90.00 -> $111.00N/AView Rating Details
9/12/2016Morgan StanleyReiterated RatingHold$104.00N/AView Rating Details
8/8/2016Citigroup IncLower Price TargetNeutral$115.00 -> $108.00N/AView Rating Details
8/3/2016FBR & CoReiterated RatingOutperform$120.00N/AView Rating Details
5/5/2016MacquarieReiterated RatingOutperform$115.00N/AView Rating Details
5/4/2016Royal Bank of CanadaReiterated RatingOutperform$110.00 -> $115.00N/AView Rating Details
2/10/2016Goldman Sachs Group IncBoost Price TargetNeutral$106.00 -> $110.00N/AView Rating Details
11/3/2015S&P Equity ResearchUpgradeStrong-Buy$121.00N/AView Rating Details
11/2/2015Raymond James Financial, Inc.Boost Price TargetOutperform$105.00 -> $110.00N/AView Rating Details
11/2/2015BMO Capital MarketsBoost Price TargetOutperform$103.00 -> $113.00N/AView Rating Details
11/2/2015JPMorgan Chase & Co.Lower Price TargetOverweight$128.00 -> $123.00N/AView Rating Details
10/21/2015Cowen and CompanyLower Price Target$118.00 -> $113.00N/AView Rating Details
(Data available from 4/28/2015 forward)


Earnings History for CVS Health Corp (NYSE:CVS)
Earnings by Quarter for CVS Health Corp (NYSE:CVS)
Earnings History by Quarter for CVS Health Corp (NYSE:CVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/9/2017Q416$1.67$1.71$46.56 billion$46.00 billionViewListenView Earnings Details
11/8/2016Q316$1.57$1.64$45.29 billion$44.60 billionViewListenView Earnings Details
8/2/2016Q216$1.30$1.32$44.28 billion$43.70 billionViewN/AView Earnings Details
5/3/2016Q116$1.16$1.18$43.01 billion$43.20 billionViewN/AView Earnings Details
2/9/2016Q415$1.53$1.53$41.12 billion$41.15 billionViewN/AView Earnings Details
10/30/2015Q315$1.29$1.28$37.81 billion$38.50 billionViewListenView Earnings Details
8/4/2015Q215$1.20$1.22$37.18 billion$37.20 billionViewN/AView Earnings Details
5/1/2015Q115$1.08$1.14$35.93 billion$36.30 billionViewN/AView Earnings Details
2/10/2015Q414$1.21$1.21$36.06 billion$37.06 billionViewN/AView Earnings Details
11/4/2014Q314$1.13$1.15$34.74 billion$35.00 billionViewN/AView Earnings Details
8/5/2014Q214$1.10$1.13$33.47 billion$34.60 billionViewN/AView Earnings Details
5/2/2014Q114$1.05$1.02$32.31 billion$32.70 billionViewN/AView Earnings Details
2/11/2014Q413$1.11$1.12$32.67 million$32.80 millionViewN/AView Earnings Details
11/5/2013Q313$1.02$1.05$31.53 billion$32.00 billionViewListenView Earnings Details
8/6/2013Q2 2013$0.96$0.97$31.13 billion$31.25 billionViewListenView Earnings Details
5/1/2013Q113$0.79$0.83$30.36 billion$30.76 billionViewListenView Earnings Details
2/6/2013Q4 2012$1.10$1.14$31.13 billion$31.40 billionViewListenView Earnings Details
11/6/2012Q312$0.84$0.85$30.09 billion$30.23 billionViewN/AView Earnings Details
8/7/2012$0.80$0.81ViewN/AView Earnings Details
5/2/2012$0.63$0.65ViewN/AView Earnings Details
11/3/2011$0.68$0.70ViewN/AView Earnings Details
8/4/2011$0.65$0.65ViewN/AView Earnings Details
5/5/2011$0.55$0.57ViewN/AView Earnings Details
2/3/2011$0.79$0.80ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CVS Health Corp (NYSE:CVS)
2017 EPS Consensus Estimate: $5.87
2018 EPS Consensus Estimate: $6.50
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$1.09$1.33$1.18
Q2 20174$1.29$1.35$1.33
Q3 20174$1.49$1.65$1.59
Q4 20174$1.70$1.92$1.77
Q1 20183$1.23$1.49$1.35
Q2 20183$1.42$1.62$1.49
Q3 20182$1.72$1.75$1.74
Q4 20182$1.91$1.93$1.92
(Data provided by Zacks Investment Research)


Current Dividend Information for CVS Health Corp (NYSE:CVS)
Next Dividend:5/1/2017
Annual Dividend:$2.00
Dividend Yield:2.42%
Dividend Growth:23.60% (3 Year Average)
Payout Ratio:40.65% (Trailing 12 Months of Earnings)
34.13% (Based on This Year's Estimates)
31.40% (Based on Next Year's Estimates)
Track Record:9 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for CVS Health Corp (NYSE:CVS)

Dividend History by Quarter for CVS Health Corp (NYSE:CVS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for CVS Health Corp (NYSE:CVS)
Insider Ownership Percentage: 0.58%
Institutional Ownership Percentage: 81.29%
Insider Trades by Quarter for CVS Health Corp (NYSE:CVS)
Institutional Ownership by Quarter for CVS Health Corp (NYSE:CVS)
Insider Trades by Quarter for CVS Health Corp (NYSE:CVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/21/2017Troyen A BrennanEVPSell23,849$78.73$1,877,631.77View SEC Filing  
3/17/2017Eva C BorattoEVPSell6,029$79.60$479,908.40View SEC Filing  
3/13/2017Andrew SussmanEVPSell14,104$80.40$1,133,961.60View SEC Filing  
3/10/2017David M DentonCFOSell95,618$80.68$7,714,460.24View SEC Filing  
2/16/2017Jonathan C RobertsEVPSell61,196$80.00$4,895,680.00View SEC Filing  
5/5/2016Larry J MerloCEOSell38,247$105.00$4,015,935.00View SEC Filing  
5/5/2016Troyen A BrennanEVPSell7,517$105.00$789,285.00View SEC Filing  
4/1/2016Stephen J GoldEVPSell21,922$105.00$2,301,810.00View SEC Filing  
3/9/2016Larry J MerloCEOSell38,247$100.00$3,824,700.00View SEC Filing  
2/11/2016Jonathan C. RobertsEVPSell23,355$92.86$2,168,745.30View SEC Filing  
2/1/2016Larry J. MerloCEOSell46,393$96.14$4,460,223.02View SEC Filing  
1/11/2016Larry J. MerloCEOSell46,393$95.00$4,407,335.00View SEC Filing  
10/27/2015Troyen A. BrennanEVPSell23,603$105.00$2,478,315.00View SEC Filing  
7/20/2015Eva C BorattoSVPSell22,107$110.34$2,439,286.38View SEC Filing  
7/15/2015Lisa BisacciaEVPSell49,908$110.00$5,489,880.00View SEC Filing  
6/1/2015C David Brown IIDirectorSell10,000$102.57$1,025,700.00View SEC Filing  
5/1/2015C David Brown IIDirectorSell15,000$100.27$1,504,050.00View SEC Filing  
4/10/2015Andrew SussmanEVPSell17,638$102.38$1,805,778.44View SEC Filing  
4/2/2015Troyen A BrennanEVPSell33,384$102.48$3,421,192.32View SEC Filing  
3/23/2015Troyen A BrennanEVPSell33,274$104.94$3,491,773.56View SEC Filing  
3/20/2015C David Brown IIDirectorSell25,000$104.30$2,607,500.00View SEC Filing  
1/7/2015Jonathan C RobertsEVPSell86,487$95.31$8,243,075.97View SEC Filing  
1/5/2015Larry J MerloCEOSell144,144$94.30$13,592,779.20View SEC Filing  
1/2/2015Andrew SussmanSVPSell4,220$95.67$403,727.40View SEC Filing  
1/2/2015Per Gh LofbergEVPSell347,343$95.28$33,094,841.04View SEC Filing  
11/7/2014Helena FoulkesEVPSell46,325$88.06$4,079,379.50View SEC Filing  
10/27/2014Lisa BisacciaSVPSell33,507$85.00$2,848,095.00View SEC Filing  
9/2/2014Andrew SussmanSVPSell9,020$79.45$716,639.00View SEC Filing  
8/6/2014J. David JoynerEVPSell123,516$76.10$9,399,567.60View SEC Filing  
7/21/2014Eva C BorattoSVPSell22,107$76.77$1,697,154.39View SEC Filing  
7/1/2014David M DentonCFOSell74,989$75.88$5,690,165.32View SEC Filing  
4/2/2014Eva BorattoSVPSell17,108$74.51$1,274,717.08View SEC Filing  
3/31/2014Troyen BrennanEVPSell18,867$74.33$1,402,384.11View SEC Filing  
1/3/2014David DentonCFOSell14,113$70.50$994,966.50View SEC Filing  
1/3/2014Per Gh LofbergEVPSell790,888$70.54$55,789,239.52View SEC Filing  
1/2/2014Jonathan RobertsEVPSell162,192$70.61$11,452,377.12View SEC Filing  
1/2/2014Larry MerloCEOSell228,875$70.76$16,195,195.00View SEC Filing  
12/10/2013Lisa BisacciaSVPSell12,057$68.00$819,876.00View SEC Filing  
11/18/2013Troyen BrennanEVPSell35,387$65.61$2,321,741.07View SEC Filing  
10/18/2013Eva C BorattoSVPSell11,053$60.50$668,706.50View SEC Filing  
10/11/2013Eva BorattoSVPSell11,053$59.50$657,653.50View SEC Filing  
9/13/2013Helena FoulkesEVPSell53,546$60.00$3,212,760.00View SEC Filing  
9/9/2013Helena FoulkesEVPSell47,568$58.65$2,789,863.20View SEC Filing  
9/4/2013Andrew SussmanSVPSell9,020$58.36$526,407.20View SEC Filing  
10/4/2012Andrew SussmanSVPSell9,020$49.00$441,980.00View SEC Filing  
10/1/2012Thomas M MoriartyEVPBuy6,164$48.67$300,001.88View SEC Filing  
9/13/2012David M DentonCFOSell11,526$47.00$541,722.00View SEC Filing  
8/21/2012Jean Pierre MillonDirectorSell33,726$45.73$1,542,289.98View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CVS Health Corp (NYSE:CVS)
Latest Headlines for CVS Health Corp (NYSE:CVS)
DateHeadline logoCVS Health Corp (CVS) Now Covered by Analysts at Tigress Financial - April 27 at 10:08 PM logoNarwhal Capital Management Buys CVS Health, Cousins Properties, iShares Core S&P Small-Cap, ... - Nasdaq - April 27 at 5:09 PM logoCVS Health Report Examines Public Perceptions of Opioid Epidemic, Drug Disposal Ahead of National Prescription Drug Take Back Day - April 27 at 5:09 PM logoCherokee Nation sues: CVS, Walmart flooded us with opioids - April 27 at 1:54 AM logoCVS Health Becomes #173 Most Shorted S&P 500 Component, Replacing Laboratory Corporation Of America Holdings - April 27 at 1:54 AM logoCVS Health Corp (CVS) Given Daily Coverage Optimism Rating of 0.53 - April 26 at 3:36 PM logo[$$] CVS Move Hurts Hershey, Boosts Post, Mondelez - April 25 at 4:20 PM logoCVS Health Corp. – Value Analysis (NYSE:CVS) : April 24, 2017 - April 24 at 4:28 PM logoCVS Health Corp (CVS) Receives Consensus Recommendation of "Buy" from Brokerages - April 24 at 2:48 PM logoCan CVS Health (CVS) Spring a Surprise this Earnings Season? - April 24 at 9:09 AM logoCVS Health Corp (CVS) Given Daily Media Impact Rating of 0.43 - April 23 at 12:59 PM logoToday's charts: Wal-Mart, Kroger price wars; Apple shares climb; Gap gets upgraded; CVS cuts back on candy - April 22 at 4:23 PM logoCan CVS Become The Whole Foods Of Drugstore Retailing? - April 22 at 4:23 PM logoCVS Health Corp. breached its 50 day moving average in a Bullish Manner : CVS-US : April 21, 2017 - April 21 at 4:42 PM logoBert's Recent Buy - CVS Health Corp. - Seeking Alpha - April 21 at 12:26 PM logoCVS Health Corporation To Hold First Quarter 2017 Conference Call - April 21 at 12:26 PM logoCVS Pharmacy Unveils Enhanced Customer Experience, New Store Design - April 20 at 4:44 PM logoCVS unveils new store design, removing certain chemicals from beauty products - April 20 at 4:44 PM logoCVS Health Corp. : CVS-US: Dividend Analysis : April 21st, 2017 (record date) : By the numbers : April 20, 2017 - April 20 at 4:44 PM logoVery Positive News Coverage Very Likely to Affect CVS Health Corp (CVS) Stock Price - April 20 at 1:15 PM logoCVS Reinventing The Pharmacy Business And My Next 2017 Dividend Machine - Seeking Alpha - April 20 at 5:40 AM logoCVS Health Has Its Highest Dividend Yield In Years And It's A Great Buy - April 19 at 9:35 PM logoSome vets can go to CVS 'MinuteClinics' for minor illnesses - April 19 at 12:37 PM logoSome vets can go to CVS 'MinuteClinics' for minor illnesses - April 18 at 3:26 PM logoPhoenix VA Health Care System, TriWest, and CVS Health Partner to Increase Veteran Access to Health Care Services - April 18 at 12:10 PM logoVA to Test Partnership With CVS to Reduce Veteran Wait Times - April 18 at 12:10 PM logoVA tests partnership with CVS to reduce veterans' wait times - April 18 at 10:52 AM logoFavorable News Coverage Very Likely to Effect CVS Health Corp (CVS) Stock Price - April 17 at 1:06 PM logoLiberty All-Star(R) Equity Fund March 2017 Update - April 17 at 11:56 AM logoEx-Dividend Reminder: Procter & Gamble, Colgate-Palmolive and CVS Health - April 17 at 11:56 AM logoCVS Health Stock Trades Ex-Dividend Wednesday (CVS) - April 17 at 11:56 AM logoCVS Health Stock Trades Ex-Dividend Wednesday - April 17 at 11:56 AM logoCVS Health Corp (CVS) Sees Large Decrease in Short Interest - April 17 at 7:22 AM logoHyland's teething tablets recalled over levels of toxic herb - April 15 at 10:42 AM logoHyland's teething tablets recalled over levels of toxic herb - April 14 at 4:55 PM logoCVS Health Corp (CVS) Receives Coverage Optimism Rating of 0.47 - April 14 at 11:38 AM logoCVS Health Corp Target of Unusually Large Options Trading (CVS) - April 14 at 8:30 AM logoCVS Health Corp (CVS) Expected to Announce Quarterly Sales of $44.39 Billion - April 13 at 2:10 PM logoLooking For A Healthcare Stock With Potential? Consider CVS - Seeking Alpha - April 13 at 11:47 AM logoInvestors need to proceed with caution, experts warn - April 11 at 1:00 PM logoZacks: Analysts Expect CVS Health Corp (CVS) Will Announce Earnings of $1.10 Per Share - April 11 at 10:29 AM logoCVS Health Corp (CVS) Lifted to "Buy" at Vetr Inc. - April 9 at 6:57 PM logoLanny's Recent Stock Purchase - CVS Health Corp. - April 9 at 11:34 AM logoCVS Health Corp Sees Unusually High Options Volume (CVS) - April 9 at 8:46 AM logoCVS Health Corp (CVS) Upgraded at Vetr Inc. - April 9 at 12:28 AM logoI'm Adding CVS Health To My DivGro Portfolio - April 8 at 10:20 AM logoNotable Friday Option Activity: WFM, CVS, AMT - April 7 at 4:33 PM logoWhat Was Eating Walgreens’ Top Line in 2Q17? - April 7 at 4:33 PM logoPBM Troubles Mean CVS Stock Might Not Be As Cheap As It Looks - April 7 at 9:17 AM logoHealth Care Plans Stocks on Investors' Radar -- CVS Health, Express Scripts, UnitedHealth, and Aetna - April 7 at 9:17 AM


Frequently Asked Questions for CVS Health Corp (NYSE:CVS)

What is CVS Health Corp's stock symbol?

CVS Health Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVS."

How often does CVS Health Corp pay dividends? What is the dividend yield for CVS Health Corp?

CVS Health Corp announced a quarterly dividend on Thursday, March 2nd. Shareholders of record on Friday, April 21st will be given a dividend of $0.50 per share on Monday, May 1st. This represents a $2.00 annualized dividend and a yield of 2.42%. The ex-dividend date is Wednesday, April 19th.

How were CVS Health Corp's earnings last quarter?

CVS Health Corp (NYSE:CVS) issued its quarterly earnings data on Thursday, February, 9th. The company reported $1.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.67 by $0.04. The company had revenue of $46 billion for the quarter, compared to analyst estimates of $46.56 billion. CVS Health Corp had a return on equity of 17.55% and a net margin of 3.00%. CVS Health Corp's quarterly revenue was up 11.7% compared to the same quarter last year. During the same period last year, the firm posted $1.53 earnings per share.

When will CVS Health Corp make its next earnings announcement?

CVS Health Corp is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

What guidance has CVS Health Corp issued on next quarter's earnings?

CVS Health Corp issued an update on its FY17 earnings guidance on Thursday, February, 9th. The company provided earnings per share guidance of $5.77-5.93 for the period, compared to the Thomson Reuters consensus estimate of $5.86. CVS Health Corp also updated its Q1 guidance to $1.07-1.13 EPS.

Where is CVS Health Corp's stock going? Where will CVS Health Corp's stock price be in 2017?

19 brokerages have issued 12 month price targets for CVS Health Corp's stock. Their predictions range from $77.00 to $120.00. On average, they expect CVS Health Corp's share price to reach $96.82 in the next year.

What are analysts saying about CVS Health Corp stock?

Here are some recent quotes from research analysts about CVS Health Corp stock:

  • 1. Guggenheim analysts commented, " Our recent meetings with CEO Larry Merlo, CFO Dave Denton, and VP-IR Nancy Christal further reinforced our confidence in 10% secular growth, which we believe the market is currently undervaluing, at a 13x P/E on somewhat depressed 2017E EPS. Bottom line, even in the face of secular gross margin erosion, in both segments, we believe the company should be able to grow EBIT by 5% on the back of a) natural growth in specialty Rx, b) increasingly rapid product innovation, c) a broadening set of productive relationships, and d) both COGS and SG&A reductions. In our view, this growth merits a valuation closer to a market multiple'we reiterate our Buy rating and $90 PT, implying 15% upside from current levels." (3/28/2017)
  • 2. Evercore ISI analysts commented, "While the quarter proved generally uneventful and guidance was reiterated on the surface (albeit some moving parts below ' dollar profit targets were unchanged in our view ' much of the delta related to where 4Q came out vs mid-point and lower inflation outlook), investors have reacted negatively to the lack of clarity on several key issues with respect to business model risk that in our minds is unlikely to dissipate until later in the year. We think management did an admirable job on the DIR fee issue and a reasonable job on gross to net / rebates, but the reality is that policy noise is unlikely to dissipate and the outlook for 2018 won't start to gain clarity until the summer. We think once we get initial color on the PBM selling season, a better understanding of underlying pharmacy share shifts and profit headwinds and ultimately gain a better picture of 2018 the multiple may start to see some relief. Until then CVS shares remain inexpensive and highly leveraged to tax reform and it appears as if many years of execution are being overshadowed by a tough 18 month stretch. Given how far shares have fallen and in our view strong FCF yield support we retain our Buy rating but acknowledge the path to returns from here is likely most appropriate for those with a multi-year time horizon and a 'deep value' focus." (2/9/2017)
  • 3. According to Zacks Investment Research, "CVS Health posted better-than-expected second-quarter with respected to adjusted EPS. However, revenues missed the Zacks Consensus Estimate. The company’s Pharmacy Services segment continues to benefit from growth in the Specialty Pharmacy business while the Retail Pharmacy segment is gaining from increased same-store sales. We take note of the recently completed Omnicare and Target Pharmacy buyouts which, according to CVS, are strategically perfect fits. CVS Health expects to benefit with multiple opportunities for driving enterprise value from Omnicare and Target in both the near and long term. CVS Health also expects to see market share gain in its specialty pharmacy suite of services with differentiated specialty offerings providing a high level of clinical support to patients. However, the competitive landscape remains tough. The tussle for market share gain in the PBM and retail space also warrants caution." (8/3/2016)

Are investors shorting CVS Health Corp?

CVS Health Corp saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 28,874,584 shares, an increase of 20.2% from the March 31st total of 24,018,678 shares. Based on an average daily volume of 6,208,767 shares, the days-to-cover ratio is presently 4.7 days. Approximately 2.8% of the shares of the stock are short sold.

Who owns CVS Health Corp stock?

CVS Health Corp's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.47%), First Manhattan Co. (0.26%), Focused Investors LLC (0.20%), Chevy Chase Trust Holdings Inc. (0.14%), Strs Ohio (0.13%) and Factory Mutual Insurance Co. (0.13%). Company insiders that own CVS Health Corp stock include Andrew Sussman, C David Brown II, David M Denton, Eva C Boratto, Jonathan C Roberts, Larry J Merlo, Lisa Bisaccia, Stephen J Gold and Troyen A Brennan.

Who sold CVS Health Corp stock? Who is selling CVS Health Corp stock?

CVS Health Corp's stock was sold by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., Korea Investment CORP, Huntington National Bank, Strs Ohio, First National Bank of Omaha, Acadian Asset Management LLC, Advisors Capital Management LLC and Factory Mutual Insurance Co.. Company insiders that have sold CVS Health Corp stock in the last year include Andrew Sussman, David M Denton, Eva C Boratto, Jonathan C Roberts, Larry J Merlo and Troyen A Brennan.

Who bought CVS Health Corp stock? Who is buying CVS Health Corp stock?

CVS Health Corp's stock was acquired by a variety of institutional investors in the last quarter, including River Road Asset Management LLC, Bank of Montreal Can, Focused Investors LLC, Alta Capital Management LLC, Sabal Trust CO, Retirement Systems of Alabama, Hexavest Inc. and Crestwood Advisors Group LLC.

How do I buy CVS Health Corp stock?

Shares of CVS Health Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CVS Health Corp stock cost?

One share of CVS Health Corp stock can currently be purchased for approximately $82.79.

CVS Health Corp (CVS) Chart for Friday, April, 28, 2017

This page was last updated on 4/28/2017 by Staff